Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CCR5 | P51681 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23200019 | 1.00 | MAPT (0.48) | MAPTKMT2AMEN1SMN1; SMN2MCHR1 | |
| SCHEMBL23200230 | 0.99 | MCHR1 (0.49) | MAPTKMT2AMEN1SMN1; SMN2MCHR1 | |
| SCHEMBL23718944 | 0.99 | MCHR1 (0.49) | MAPTKMT2AMEN1SMN1; SMN2MCHR1 | |
| SCHEMBL23718907 | 0.93 | MAPT (0.51) | MAPTKMT2AMEN1SMN1; SMN2MCHR1 | |
| SCHEMBL23699940 | 0.93 | MAPT (0.51) | MAPTKMT2AMEN1SMN1; SMN2MCHR1 | |
| SCHEMBL23718943 | 0.92 | MAPT (0.49) | MAPTKMT2AMEN1SMN1; SMN2MCHR1 | |
| SCHEMBL23200101 | 0.92 | MAPT (0.49) | MAPTKMT2AMEN1SMN1; SMN2MCHR1 | |
| SCHEMBL23200196 | 0.91 | MAPT (0.54) | MAPTKMT2AMEN1SMN1; SMN2MCHR1 | |
| SCHEMBL23718860 | 0.91 | MAPT (0.54) | MAPTKMT2AMEN1SMN1; SMN2MCHR1 | |
| SCHEMBL23699897 | 0.90 | MAPT (0.48) | MAPTKMT2AMEN1SMN1; SMN2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | E-THERAPEUTICS PLC (GB) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | TPH1, KYNU, TPH2 | MAPT 128/4885KMT2A 3246/4885MEN1 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.